Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111


Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.

Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, Oyon DE, Fakurnejad S, Ampie L, Kesavabhotla K, Kaur R, Kaur G, Biyashev D, Unruh DJ, Horbinski CM, James CD, Parsa AT, Bloch O.

Clin Cancer Res. 2019 Jun 15;25(12):3643-3657. doi: 10.1158/1078-0432.CCR-18-2402. Epub 2019 Mar 1.


Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.

Neuro Oncol. 2017 Jun 1;19(6):796-807. doi: 10.1093/neuonc/now287.


Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.

Hardcastle J, Mills L, Malo CS, Jin F, Kurokawa C, Geekiyanage H, Schroeder M, Sarkaria J, Johnson AJ, Galanis E.

Neuro Oncol. 2017 Apr 1;19(4):493-502. doi: 10.1093/neuonc/now179.


Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.

Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y, Oshiumi H.

Cancer Res. 2018 Sep 1;78(17):5011-5022. doi: 10.1158/0008-5472.CAN-18-0118. Epub 2018 Jul 2.


Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Liechtenstein T, Perez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, Lanna A, Ridder M, Guerrero-Setas D, Breckpot K, Escors D.

Oncoimmunology. 2014 Jul 3;3(7):e945378. eCollection 2014.


The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.

Qian J, Wang C, Wang B, Yang J, Wang Y, Luo F, Xu J, Zhao C, Liu R, Chu Y.

J Neuroinflammation. 2018 Oct 17;15(1):290. doi: 10.1186/s12974-018-1330-2.


The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.

Lee JW, Zhang Y, Eoh KJ, Sharma R, Sanmamed MF, Wu J, Choi J, Park HS, Iwasaki A, Kaftan E, Chen L, Papadimitrakopoulou V, Herbst RS, Koo JS.

J Thorac Oncol. 2019 Jun;14(6):1046-1060. doi: 10.1016/j.jtho.2019.02.004. Epub 2019 Feb 13.


Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.

Wu A, Maxwell R, Xia Y, Cardarelli P, Oyasu M, Belcaid Z, Kim E, Hung A, Luksik AS, Garzon-Muvdi T, Jackson CM, Mathios D, Theodros D, Cogswell J, Brem H, Pardoll DM, Lim M.

J Neurooncol. 2019 Jun;143(2):241-249. doi: 10.1007/s11060-019-03172-5. Epub 2019 Apr 25.


Systemic and local immunosuppression in patients with high-grade meningiomas.

Li YD, Veliceasa D, Lamano JB, Lamano JB, Kaur G, Biyashev D, Horbinski CM, Kruser TJ, Bloch O.

Cancer Immunol Immunother. 2019 Jun;68(6):999-1009. doi: 10.1007/s00262-019-02342-8. Epub 2019 Apr 27.


Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.

Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O'Rourke DM, D'Ambrosio A, Bruce JN, Parsa AT.

Clin Cancer Res. 2017 Jul 15;23(14):3575-3584. doi: 10.1158/1078-0432.CCR-16-1369. Epub 2017 Feb 13.


Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer.

Wang Y, Liu J, Yang X, Liu Y, Liu Y, Li Y, Sun L, Yang X, Niu H.

Onco Targets Ther. 2018 May 16;11:2891-2899. doi: 10.2147/OTT.S165840. eCollection 2018.


Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.

Ostrand-Rosenberg S, Horn LA, Ciavattone NG.

Front Oncol. 2019 Apr 2;9:215. doi: 10.3389/fonc.2019.00215. eCollection 2019. Review.


Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.

Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, Brochez L.

Oncoimmunology. 2015 Apr 2;4(3):e982382. eCollection 2015 Mar.


Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.

Takeda Y, Yoshida S, Takashima K, Ishii-Mugikura N, Shime H, Seya T, Matsumoto M.

Cancer Sci. 2018 Jul;109(7):2119-2129. doi: 10.1111/cas.13649. Epub 2018 Jun 16.


PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients.

Liu Y, Carlsson R, Ambjørn M, Hasan M, Badn W, Darabi A, Siesjö P, Issazadeh-Navikas S.

J Neurosci. 2013 Aug 28;33(35):14231-45. doi: 10.1523/JNEUROSCI.5812-12.2013.


Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.

Duraiswamy J, Freeman GJ, Coukos G.

Cancer Res. 2013 Dec 1;73(23):6900-12. doi: 10.1158/0008-5472.CAN-13-1550. Epub 2013 Aug 23.


Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.

Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN.

J Immunother Cancer. 2013 Aug 29;1:15. doi: 10.1186/2051-1426-1-15. eCollection 2013.


The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.

DiDomenico J, Lamano JB, Oyon D, Li Y, Veliceasa D, Kaur G, Ampie L, Choy W, Lamano JB, Bloch O.

Oncoimmunology. 2018 Apr 25;7(7):e1448329. doi: 10.1080/2162402X.2018.1448329. eCollection 2018.


PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients.

Han J, Hong Y, Lee YS.

J Pathol Transl Med. 2017 Jan;51(1):40-48. doi: 10.4132/jptm.2016.08.31. Epub 2016 Dec 15.


Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.

Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW.

Blood. 2016 Mar 17;127(11):1449-58. doi: 10.1182/blood-2015-06-652503. Epub 2015 Dec 28.

Supplemental Content

Support Center